Effect of Reduced Vasopressors on Mortality in ECMO-supported Cardiogenic Shock Patients

Recruiting now

Conditions studied: Cardiogenic Shock, Extracorporeal Membrane Oxygenation, Vasopressors, Hemodynamic Management, Critical Care, Heart Failure

In brief

The goal of this observational study is to learn about the association between vasopressor exposure levels and outcomes in adults with cardiogenic shock receiving VA-ECMO. The main question it aims to answer is: Does reduced exposure to vasopressors lower the 30-day mortality in patients with cardiogenic shock when receiving ECMO support? Participants who are receiving ECMO support for cardiogenic shock as part of their regular medical care will have their data collected, including information about their vasopressor use and mortality outcomes, over the course of the study.

Key facts

Study ID

NCT06862700

Run by

Xiaotong Hou

People needed

534

Starts

2025-02-26

Expected to finish

2028-01-01

Last updated by the study team

2025-03-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults (≥18 years) with cardiogenic shock requiring VA-ECMO support.
• First-time ECMO initiation.
• Venoarterial ECMO (VA-ECMO) as the initial mode.

You may not qualify if…

• Age <18 years.
• Severe pulmonary hypertension.
• Vasopressor use for non-shock indications (e.g., bleeding, post-cardiopulmonary bypass vasoplegia).
• Severe missing data.

Where it is running

• Beijing Anzhen Hospital — Beijing, Beijing Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.